Silo Pharma, Inc. (SILO) - Dilution Analysis

8-K filing: Stock split 1-for-15 | Outstanding: 16,266,593 → 1,084,439

POS AM filing: Silo Pharma, Inc. is offering common stock purchase warrants to purchase up to 4,773,340 shares of common stock, as well as registering the shares of common stock issuable upon exercise of the common stock purchase warrants, and placement agent warrants.

8-K filing: Silo Pharma, Inc. issued 2,100,000 shares of its common stock to Many Ads Inc. as consideration for the purchase of certain software and domain names.

10-K filing | 14.2M shares outstanding

10-Q filing | 13.3M shares outstanding

8-K filing: Silo Pharma, Inc. completed a private placement offering of 2,857,143 shares of common stock at a price of $0.875 per share, resulting in gross proceeds of approximately $2.5 million, and issued warrants to purchase one share of common stock for each share purchased. ($2.5M proceeds)

10-Q filing | 9.4M shares outstanding

8-K filing: Silo Pharma, Inc. established a cryptocurrency advisory board and granted options to Corwin Yu to purchase 45,000 shares of common stock at an exercise price of $0.7757, vesting in 12 equal monthly installments.

8-K filing: Silo Pharma, Inc. entered into an asset purchase agreement with MAVS Holdings LLC to purchase certain software and domain names, issuing 750,000 shares of its common stock as consideration.

8-K filing: Silo Pharma, Inc. completed a public offering of common stock, prefunded warrants, and warrants, raising approximately $1.56 million in net proceeds.

10-Q filing | 4.5M shares outstanding

S-1/A filing: The company is offering shares of its common stock together with series A-1 and A-2 common stock purchase warrants, and pre-funded warrants, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

S-1/A filing: The company will issue warrants to Wainwright or its designees to purchase common stock equal to 7.5% of the aggregate number of shares placed in each offering, excluding ATM offerings.

S-1 filing: This S-1 filing outlines a public offering by Silo Pharma, Inc. for a combination of common stock, warrants, and pre-funded warrants, aiming to raise $15,000,000 for general working capital purposes, with H.C. Wainwright & Co., LLC as the placement agent.

POS AM filing: This prospectus relates to the offer and resale by the Selling Shareholders of up to 820,911 shares of Common Stock issuable upon the exercise of the Warrants.

10-K filing | 4.5M shares outstanding

10-Q filing | 4.3M shares outstanding

S-1 filing: This prospectus relates to the offer and resale by the Selling Shareholders of up to 820,911 shares of Common Stock issuable upon the exercise of the Warrants.

10-Q filing | 4.5M shares outstanding

S-1/A filing: This prospectus relates to the offer and resale of up to an aggregate of 1,043,739 shares of common stock, consisting of shares of Common Stock issuable upon the exercise of common stock purchase warrants.

8-K filing: Silo Pharma, Inc. sold 763,638 shares of common stock at $2.75 per share in a completed offering, along with unregistered warrants to purchase one share of common stock for each share purchased, with gross proceeds of approximately $2.1 million. ($2.1M proceeds)

S-1 filing: This prospectus relates to the offer and resale of up to an aggregate of 1,043,739 shares of common stock, par value $0.0001 per share, of Silo Pharma, Inc., consisting of shares of Common Stock issuable upon the exercise of warrants.

8-K filing: Silo Pharma, Inc. completed an offering of 883,395 shares of common stock, pre-funded warrants to purchase up to 34,037 shares, and unregistered warrants to purchase one share of common stock for each share purchased, with gross proceeds of approximately $2 million. ($2.0M proceeds)

10-Q filing | 2.9M shares outstanding

8-K filing: Silo Pharma, Inc. approved an extension of its stock repurchase program for up to $1.0 million of its common stock until April 30, 2024, and as of March 31, 2024, had repurchased 315,462 shares for $566,803. ($0.57M proceeds)

10-K filing | 3.1M shares outstanding

S-3/A filing: This S-3/A filing relates to the offering of common stock, preferred stock, and debt securities under a shelf registration statement.

S-3 filing: S-3 filing for SILO Pharma, Inc. indicating a potential offering of common stock, preferred stock, debt securities, or warrants with an aggregate initial offering price not exceeding $25,000,000, subject to completion.

10-Q filing | 3.1M shares outstanding

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-K filing | 3.2M shares outstanding

10-Q filing | 3.1M shares outstanding

8-K filing: Silo Pharma, Inc. closed a public offering of 1,150,000 shares of common stock at $5.00 per share, resulting in net proceeds of approximately $4.83 million, and issued warrants to purchase up to 57,500 shares of common stock to the representative of the Underwriters. ($5.75M proceeds)

S-1/A filing: This prospectus relates to the sale by Silo Pharma, Inc. of 588,236 shares of common stock at an assumed public offering price of $8.50 per share.

8-K filing: Stock split 1-for-50 | Outstanding: 99,395,304 → 1,987,906

S-1/A filing: This S-1/A filing from Silo Pharma, Inc. relates to the offering of 766,872 shares of common stock with Laidlaw & Company (UK) Ltd. as the underwriter, and includes a warrant offering equal to 5% of the closing shares sold.

S-1/A filing: This S-1/A filing from Silo Pharma, Inc. relates to the sale of 766,872 shares of common stock at an assumed price of $6.52 per share, with Laidlaw & Company (UK) Ltd. as the underwriter. The company intends to use the net proceeds for product development, marketing, and general corporate purposes.

10-Q filing | 99.4M shares outstanding

S-1/A filing: Silo Pharma, Inc. is filing an S-1/A to sell 1,250,000 shares of common stock together with warrants to purchase 1,250,000 shares of common stock, with an underwriter option to purchase up to an additional 187,500 shares of common stock and/or warrants.

10-Q filing | 98.6M shares outstanding

10-K filing | 95.9M shares outstanding

S-1 filing: This is an S-1 filing for a common stock offering by Silo Pharma, Inc. with the intention to list on the Nasdaq Capital Market; proceeds will be used for product development, marketing, and working capital.

10-Q filing | 98.6M shares outstanding

8-K filing: DatChat, Inc. completed its initial public offering of 2,891,567 units consisting of common stock and series A warrants to purchase up to 2,891,567 shares of common stock at a public offering price of $4.15 per unit. ($12.0M proceeds)

10-Q filing | 98.7M shares outstanding

10-Q filing | 98.7M shares outstanding

8-K filing: The company converted 4,048 shares of Series C Convertible Preferred Stock into 13,495,014 shares of common stock on April 14, 2021.

S-1/A filing: This S-1/A filing registers the resale of up to 28,506,646 shares of common stock by selling stockholders, including shares issuable upon exercise of warrants and conversion of Series C Preferred Stock.

10-K filing | 85.2M shares outstanding

S-1 filing: This S-1 filing relates to the resale of common stock by selling stockholders of Silo Pharma, Inc.

8-K filing: Silo Pharma, Inc. entered into securities purchase agreements for the sale of 4,276 shares of Series C convertible preferred stock and warrants to purchase 14,253,333 shares of common stock for gross proceeds of $4,276,000. ($4.28M proceeds)

10-Q filing | 23.6M shares outstanding

10-Q filing | 23.6M shares outstanding

S-1 filing: This S-1 filing describes recent developments including private placements, exchange of convertible notes and preferred stock for common stock, subscription agreements, and consulting agreements involving the issuance of common stock.

10-Q filing | 83.1M shares outstanding

8-K filing: The company completed multiple equity transactions including the exchange of convertible notes and Series B preferred stock for common stock, the issuance of common stock through subscription and consulting agreements, and the issuance of common stock for advisory services. ($0.79M proceeds)

10-K filing | 23.6M shares outstanding